Immunomic Therapeutics to Participate at Sach’s 5th Annual Immuno-oncology BD&L and Investment Forum

ROCKVILLE, Md.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/allergies?src=hash" target="_blank"gt;#allergieslt;/agt;–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based
biotechnology company, announced today that the company will present at
the 5^th Annual Immuno-oncology BD&L and Investment Forum
being held in Chicago, IL, May 31, 2019. Sia Anagnostou, Immunomic’s
Senior Director of Corporate Development, will present a company
overview and will discuss ITI’s recently expanded, investigational
UNiversal Intracellular Targeted Expression (UNITE) platform and its
application in immuno-oncology, specifically glioblastoma multiforme
(GBM). ITI’s technology platform has the potential to utilize the body’s
natural biochemistry to develop a broad immune response and is currently
being employed in a Phase II clinical trial as a cancer immunotherapy.

Presentation details are as follows:

Title: Immunomic Therapeutics, Pioneering Vaccines That Transform
Lives
Panel Date and Time: Friday, May 31, 2019 10:30 AM
Track
& Room: PR Track C, Room Sinclair North
Place:
Waldorf Astoria Chicago Hotel, Chicago, Illinois

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular
Targeted Expression, is thought to work by encoding the Lysosomal
Associated Membrane Protein, an endogenous protein in humans. In this
way, ITI’s vaccines (DNA or RNA) have the potential to utilize the
body’s natural biochemistry to develop a broad immune response including
antibody production, cytokine release and critical immunological memory.
This approach could put UNITE technology at the crossroads of
immunotherapies in a number of illnesses, including cancer, allergy and
infectious diseases. UNITE is currently being employed in Phase II
clinical trials as a cancer immunotherapy. ITI is also collaborating
with academic centers and biotechnology companies to study the use of
UNITE in cancer types of high mortality, including cases where there are
limited treatment options like glioblastoma and acute myeloid leukemia.
ITI believes that these early clinical studies may provide a proof of
concept for UNITE therapy in cancer, and if successful, set the stage
for future studies, including combinations in these tumor types and
others. Preclinical data is currently being developed to explore whether
LAMP nucleic acid constructs may amplify and activate the immune
response in highly immunogenic tumor types and be used to create immune
responses to tumor types that otherwise do not provoke an immune
response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage
biotechnology company pioneering the development of vaccines through its
proprietary technology platform, UNiversal Intracellular Targeted
Expression (UNITE), which is designed to utilize the body’s natural
biochemistry to develop vaccines that generate broad immune responses.
ITI’s UNITE platform could potentially have broad therapeutic
applications in oncology, including viral antigens, cancer antigens,
neoantigens and antigen-derived antibodies as biologics and ITI has
built a large pipeline from UNITE with six oncology programs and two
allergy programs. ITI has entered into a significant allergy partnership
with Astellas Pharma and has formed several academic collaborations with
leading Immuno-oncology researchers at Fred Hutchinson Cancer Research
Institute, Johns Hopkins University of Medicine, Duke University. ITI
maintains its headquarters in Rockville, Maryland. For more information,
please visit www.immunomix.com.

Contacts

Company Contact:
Sia Anagnostou
[email protected]
717-327-1822

Media Contact:
Amy Conrad
Juniper Point
[email protected]
858-366-3243